<--- Back to Details
First PageDocument Content
Cancer research / Multiple myeloma / Minimal residual disease / International Myeloma Working Group / Stem cells / Lenalidomide / Plasma cell / Bone marrow examination / Thalidomide / Medicine / Hematologic neoplasms / Immunosuppressants
Cancer research
Multiple myeloma
Minimal residual disease
International Myeloma Working Group
Stem cells
Lenalidomide
Plasma cell
Bone marrow examination
Thalidomide
Medicine
Hematologic neoplasms
Immunosuppressants

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 396,29 KB

Share Document on Facebook

Similar Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID® safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide] capsules,

DocID: 1tonS - View Document

Revlimid, INN-lenalidomide

DocID: 1szTz - View Document

Medicine / Clinical medicine / Hematology / Blood tests / Multiple myeloma / RTT / Serum free light-chain measurement / Paraproteinemia / Monoclonal gammopathy of undetermined significance / Plasma cell dyscrasia / Lenalidomide / Plasma cell

Pipette, Seite 11–13 Monoklonale Gammopathien: Neue IMWG-Kriterien und Labortests für die Diagnose, Prognose und Verlaufskontrolle des Multiplen Myeloms Luca Bernasconi, Esther Mundwiler Referenzen 1.

DocID: 1rfhH - View Document

Chemistry / Organic chemistry / Clinical medicine / Carfilzomib / Epoxides / Morpholines / Peptides / Aromatic amines / Immunosuppressants / Lenalidomide / Bortezomib / Dex

12-AUG:10 MMYEL ACCRUAL REPORT - Open and Recently Closed Studies SWOG/ Support STUDY

DocID: 1qMvA - View Document

Gynecologic oncology / Ovarian cancer

PUBLICATION DU GINECO Année 2014 Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A,.Lortholary A, PujadeLauraine E. A phase II study of lenalidomide in platinum-sensitive recurrent

DocID: 1qvQ0 - View Document